Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04995003
Title HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Baylor College of Medicine
Indications

sarcoma

Therapies

HER2 CAR-T cells + Nivolumab

Cyclophosphamide + Fludarabine + HER2 CAR-T cells + Pembrolizumab

Age Groups: adult | child
Covered Countries USA


No variant requirements are available.